#United States #Aethlon Medical #Hemopurifier #Long COVID #Santa Fe, NM

Aethlon Medical Unveils Pre-Clinical Data at Keystone Symposium

Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering medical therapeutic company, is set to present vital pre-clinical data regarding Long COVID at the forthcoming Keystone Symposium, which focuses on Long COVID and other post-acute infection syndromes. This symposium will take place at the Eldorado Hotel & Spa in Santa Fe, New Mexico, from August 10 to August 13, 2025.

Long COVID, characterized by lingering symptoms that persist well past the initial SARS-CoV-2 infection, affects millions of individuals worldwide. In the United States alone, it is estimated that between 44 and 48 million people are suffering from this debilitating condition, which can lead to serious complications like fatigue, cognitive disturbances, and respiratory issues. The estimated economic burden of Long COVID is staggering, projected at around $2 billion for those experiencing prolonged symptoms. Despite significant investments exceeding $1 billion in research funding designated for Long COVID studies, no successful treatment has emerged.

At the symposium, Aethlon Medical will present an abstract titled "_Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier_". This presentation is expected to shed light on the role extracellular vesicles (EVs) play in the Long COVID pathology. EVs, which are tiny particles ranging from 50 to 500 nanometers in diameter, are released by various cell types and are vital for cell-to-cell communication. Emerging evidence links these EVs to the adverse effects observed in Long COVID, including viral persistence and inflammatory responses.

Aethlon's cutting-edge device, the Hemopurifier®, employs a novel mechanism to extract harmful EVs from the bloodstream. This investigational device utilizes a proprietary affinity resin to bind and remove EVs, which may harbor pathogenic materials and contribute to long-term complications. The Hemopurifier® has shown promise in previous studies involving patients with severe acute COVID-19 infections, where it successfully removed EVs from the patient's bloodstream.

For the upcoming Keystone Symposium, Aethlon Medical collaborated with the University of California San Francisco (UCSF) Medical Center's Long COVID clinic. Researchers evaluated plasma samples from individuals suffering from Long COVID against control samples from participants who have fully recovered from COVID-19. The aim is to determine whether the EVs in patients with Long COVID exhibit binding characteristics that indicate the presence of particular sugar structures, specifically mannose, observed in the Hemopurifier®'s affinity resin.

The study will detail how both larger and smaller EVs interact with the Galanthus Nivalis Agglutinin (GNA) lectin, fundamental to the Hemopurifier's mechanism. The poster presentation will be delivered by Dr. Steven P. LaRosa, Chief Medical Officer of Aethlon Medical, at 7:30 PM MDT on August 12, 2025.

The findings presented at this symposium could open new avenues for therapeutic approaches to managing Long COVID, potentially offering hope to millions suffering from this persistent condition. Following the presentation, the poster will also be available on Aethlon Medical's official website, along with additional resources about the Hemopurifier® and its applications in combating life-threatening infections and cancers.

Aethlon Medical is dedicated to advancing the science of immunotherapies and is recognized for its innovative approach to the treatment of cancer and viral infections. The Hemopurifier® has received FDA-designated Breakthrough Device status, providing exciting potential for patients battling advanced or metastatic cancer and is actively seeking pathways to improve patient outcomes in the journey against severe viral infections.

For more detailed updates and breakthroughs, further information will be accessible on Aethlon Medical's website.